Overview
From a portfolio lens, Arbitrum ($543.44M) and Injective ($490.41M) offer different beta to bitcoin cycles. The overview below keeps the facts first and the narrative second.
Quick winners
Full comparison
| Metric | ARB | INJ |
|---|---|---|
| Price | $0.081000 | $5.00 |
| Market Cap | $543.44M | $490.41M |
| FDV | — | — |
| Volume 24h | $4.69M | $2.50M |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 95.00 | 99.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.47% | +5.97% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | ARB | INJ |
|---|---|---|
| 1H | — | — |
| 24H | +3.45% | +1.77% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | ARB | INJ |
|---|---|---|
| RSI | 42.16 | 49.29 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.00 | 0.29 |
| ADX | 22.88 | 12.19 |
| Support | 0.08 | 4.91 |
| Resistance | 0.09 | 5.07 |
| Trend | bearish | neutral |
| Momentum | — | — |
| Signal | neutral | neutral |
Automatic technical analysis
Technically, Arbitrum shows RSI 42.16 with trend bias bearish, while Injective sits at RSI 49.29 (neutral). Divergences between momentum and price should be confirmed on higher timeframes.
Fundamentals
| Metric | ARB | INJ |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 4.00 | 0.00 |
| Github activity | 101.00 | 118.00 |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Arbitrum
Injective
Pros and cons
Pros of Arbitrum
- Higher ranking for Arbitrum can translate into tighter spreads on major venues.
- Arbitrum has an established coin page footprint on PEPS for continuous monitoring.
- ARB often anchors narratives that attract sustained media and analyst coverage.
Cons of Arbitrum
- Regulatory or macro headlines can hit Arbitrum harder simply because it is more visible.
- Indicator stacks on Arbitrum may stay stretched longer than expected in strong trends.
Pros of Injective
- Narrative optionality around Injective can reprice quickly when catalysts appear.
- Diversifying versus Arbitrum with Injective can change portfolio factor exposure.
- Injective can offer higher relative beta when market attention rotates toward its niche.
- Active volume bursts on INJ sometimes precede sharper tactical moves.
Cons of Injective
- Trend failures on Injective often travel faster than on more established assets.
- Smaller book depth versus large caps can increase slippage for Injective.
- Higher volatility on INJ cuts both ways and demands stricter risk limits.
- Weaker market-cap standing may leave Injective more exposed to liquidity droughts.
Which looks stronger right now?
On the latest snapshot, market-cap leadership belongs to Arbitrum, while short-term performance leans toward Arbitrum. That mix suggests relative strength can flip quickly, so size risk accordingly.
AI summary
PEPS synthesizes module output into a readable pair brief. Headline stats put Arbitrum at $0.081000 and Injective at $5.00. Relative performance over 24h (Arbitrum) is a short window. Pair it with 30d/1y rows before inferring regime change. Return to related comparisons and individual coin intelligence pages to validate whether the relative story still holds after fresh prints.
FAQ
Which is better, Arbitrum or Injective?
“Better” depends on horizon and risk. Arbitrum leads on market cap today, while Arbitrum leads the 24h move — neither is a guarantee.
Which has more upside potential, ARB or INJ?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Arbitrum and Injective.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Arbitrum currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Arbitrum, but longer windows can disagree.